 3. Patient must have relapsed or refractory non-Hodgkins lymphoma NHL or Hodgkins disease. Patients must have CNS 1 disease. Patient must have histologic verification of disease at original diagnosis. Patient must have measurable disease documented by clinical or radiographic criteria or bone marrow disease present at study entry. 